Your browser doesn't support javascript.
loading
Effect of RAD18-siRNA on proliferation and chemotherapy sensitivity of human esophageal squamous cell carcinoma ECA-109 cells / 浙江大学学报·医学版
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-239577
Biblioteca responsável: WPRO
ABSTRACT
To investigate the effect of RAD18-siRNA on cell proliferation and chemotherapy sensitivity of esophageal squamous cell carcinoma (ESCC) ECA-109 cells.RAD18-siRNA was transfected into human ECA-109 cells by Lipofectamine 3000. Quantitative PCR and Western blot were performed to detect RAD18 and CyclinD1 expression; CCK-8 assay was used to determine cell proliferation and chemotherapy drug sensitivity; flow cytometry was used to determine cell cycle. Correlation between RAD18 and CyclinD1 mRNA expression was analyzed by Pearson's correlation.Compared with non-transfected cells, the expression of RAD18 in RAD18-siRNA group was significantly decreased (<0.05). The cell proliferation was inhibited (<0.05) and the cell number of G1 phase was increased, G2/M phase cells decreased (<0.05) in RAD18-siRNA group. After treatment with different concentrations of cisplatin or 5-FU, the survival rate of the two cell groups was reduced (all<0.05), and the IC50 of RAD18-siRNA group was significantly lower than that of non-transfected group (<0.05). The mRNA expression of RAD18 was positively correlated with CyclinD1 expression in ESCC tissues(=0.478,<0.01).Down-regulated expression of RAD18 can decrease the cell proliferation and increase chemo-sensitivity of ESCC cells, and CyclinD1 may participate in the process.
Assuntos
Texto completo: Disponível Contexto em Saúde: ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis Problema de saúde: Doenças do Sistema Digestório / Neoplasia Esofágica Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Farmacologia / Neoplasias Esofágicas / Ensaios de Seleção de Medicamentos Antitumorais / Carcinoma de Células Escamosas / Transfecção / Regulação para Baixo / Ciclo Celular / Adjuvantes Farmacêuticos / Fase G1 / Fase G2 Limite: Humanos Idioma: Chinês Revista: Journal of Zhejiang University. Medical sciences Ano de publicação: 2016 Tipo de documento: Artigo
Texto completo: Disponível Contexto em Saúde: ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis Problema de saúde: Doenças do Sistema Digestório / Neoplasia Esofágica Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Farmacologia / Neoplasias Esofágicas / Ensaios de Seleção de Medicamentos Antitumorais / Carcinoma de Células Escamosas / Transfecção / Regulação para Baixo / Ciclo Celular / Adjuvantes Farmacêuticos / Fase G1 / Fase G2 Limite: Humanos Idioma: Chinês Revista: Journal of Zhejiang University. Medical sciences Ano de publicação: 2016 Tipo de documento: Artigo
...